LinqMed and PeptiDream Announce Strategic Partnership for the Development and Commercialization of 64Cu-ATSM

LinqMed and PeptiDream Announce Strategic Partnership for the Development and Commercialization of 64Cu-ATSM in Japan – LinqMed Inc. – Innovative “Visible” Anti-Cancer Treatment with Radiopharmaceuticals

hypoxia-targeted(Hif-1a) internal radiotherapy agent, 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM)

ref:

PC data: Multiple Administrations of 64Cu-ATSM as a Novel Therapeutic Option for Glioblastoma: a Translational Study Using Mice with Xenografts - PubMed (nih.gov)

P1: Phase I clinical trial of 64Cu-ATSM for malignant brain tumors. | Journal of Clinical Oncology (ascopubs.org)


要查看或添加评论,请登录

Sun Gwan Hwang的更多文章

社区洞察

其他会员也浏览了